Ul­tragenyx stum­bles with UX007 PhI­II, shares plunge

Rare dis­ease spe­cial­ist Ul­tragenyx Phar­ma $RARE has aban­doned its ex­per­i­men­tal drug, UX007, as a treat­ment for Glut1 DS – a de­bil­i­tat­ing dis­ease char­ac­ter­ized by seizures, de­vel­op­men­tal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER